ClinicalTrials.gg
Sign In
RecruitingNCT06424028Updated May 21, 2024

Acute Right Ventricular Infarction Registry

An observational study in Inferior Wall; Transmural Myocardial Infarction and Right Ventricular Dysfunction, sponsored by National Institute of Cardiovascular Diseases, Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by National Institute of Cardiovascular Diseases, Pakistan · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

This Study aims to provide an assessment of clinical presentation, management, hospital course, and prognosis of acute right ventricular infarction presenting with or without Inferior or infero-posterior wall Myocardial Infarction and the assessment of composite adverse clinical outcome after reperfusion in-hospital and post-discharge (in 30 Days Prognosis).

Read the detailed description

After fulfilling the eligibility criteria, informed consent will be obtained from all the patients regarding using data for research while maintaining anonymity.Data will be collected for various patient, system, and procedure related characteristics with the help of a predefined structured proforma consisted of demographic data, clinical presentation, history and co-morbid conditions, and angiographic and procedural characteristics. All the recruited patients will be kept under observiton during the hospital stay and a telephonic follow-up will be carried out after 30-days of discharge and occurrence of the MACE will be recorded.

Univariate and multivariable binary logistic regression analysis will be performed to determine the clinical predictors of RVI. Odds ratio (OR) along with 95% confidence interval (CI) will be reported. The statistical significance criteria will be set as p-value\<0.05.

For data verification, 10% of the data will be cross-checked with the source document (Patient file).

02

Conditions studied

  • Inferior Wall; Transmural Myocardial Infarction
  • Right Ventricular Dysfunction
03

In context

Ventricular Dysfunction, Right

90 studies on the registry are indexed under Ventricular Dysfunction, Right; 28 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 100 across 51 observational studies indexed under Ventricular Dysfunction, Right.

Browse Ventricular Dysfunction, Right studies →

Lead sponsor

National Institute of Cardiovascular Diseases, Pakistan is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presented at a tertiary care hospital with Inferior and posterior wall MI with and without RV infarction undergoing PPCI who are fulfilling the eligibility criteria will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of Inferior, infero-lateral and infero-posterior wall MI with and without RV infarction undergoing PPCI.
  • Both male and female patients.
  • Patients of age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  • Patients who will not give consent for participation.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Interventions

  • OtherRight Ventricular Infarct

    Consecutive patients presented with isolated inferior, infero-posterior and inferolateral wall MI with or without acute right ventricular infarction.

06

What researchers measure

Primary outcomes

  1. Composite adverse clinical outcome

    Atleast one adverse event, such as pump failure, cerebrovascular accident (CVA), stent thrombosis, major bleeding, contrast-induced nephropathy (CIN), ventricular arrhythmias, or mortality.

    Time frame: Upto 30 days from admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The Hospital Medical Record number will be used as the patient identifier.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2024, 5 months after the start.

Of 25 observational studies under Ventricular Dysfunction, Right, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 26. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 21, 2024
StartActual
Jan 20, 2024
Primary completionEst.
Jul 19, 2024
CompletionEst.
Aug 19, 2024
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06424028
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
Responsible party
Dr. Rajesh Kumar (Associate Professor Adult Cardiology, National Institute of Cardiovascular Diseases, Pakistan) — Principal investigator
First posted
May 21, 2024
Start date
Jan 20, 2024
Primary completion
Jul 19, 2024 (estimated)
Completion
Aug 19, 2024 (estimated)
Last update
May 21, 2024

Study contacts

Rajesh Kumar, MBBS, FCPS
Contact
rajeshnarsoolal@gmail.com
+923337306090
Musa Karim, MSc
Contact
mkarim.nicvd@gmail.com
03323646169
Rajesh Kumar, MBBS, FCPS
principal investigator · National Institute of Cardiovascular Diaseses

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ventricular Dysfunction, Right →

Other studies from this sponsor

National Institute of Cardiovascular Diseases, Pakistan

Start the discussion